Avalo Therapeutics, Inc. (AVTX) Form 8-K — Aug 6, 2026
Avalo Therapeutics reported a net loss of $36.4 million for the second quarter of 2026, driven by increased research and development expenses of $23.4 million and general and administrative expenses of $8.1 million. The company's cash, cash equivalents, and investments totaled $472.2 million as of June 30, 2026, providing a strong financial runway into 2029.
Key figures
- Eps
- -0.83
- Eps Beat
- 0
- Net Loss
- -36358000
- Revenue
- 0
- Net Income
- -36358000
- Cash Position
- 472200000
- Shares Outstanding
- 43602044
- Research And Development
- 23418000
- General And Administrative
- 8099000
Price after filing
1 day: +1.7%7 days: +5.0%30 days: +3.8%
Close on the filing date to close N calendar days later (from $18.53). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.